Emergent wins FDA all-clear to restart J&J COVID-19 vaccine production in Baltimore

Some three months after federal officials called for a manufacturing pause, Emergent BioSolutions has righted the ship at its beleaguered Bayview facility.

Emergent won the FDA’s blessing to restart production of Johnson & Johnson’s COVID-19 vaccine at its Baltimore, Maryland, plant, the company said Thursday. The move follows “extensive” FDA reviews, plus “close coordination” with the agency and J&J on the quality enhancement plan Emergent debuted in May.